natgillin/translations-raw huggingface dataset:
with a compound of formula (ii) wherein Ar is as defined in claim 1; 
sa spojem formule (ii): gdje Z1, Z2, Z3, Z4 i Z5 su kao što su definirani u patentnom zahtjevu 1;
A method for the preparation of the compound of formula I or a salt thereof comprising reacting a compound of formula VIa (i.e. 
Postupak pripreme spoja formule I ili njegove soli koji obuhvaća reakciju spoja formule VIa (tj.
or a pharmaceutically acceptable salt thereof. The compound of claim 1 wherein at least one of E1a and E1b is —N(H)(alkoxycarbonyl). 
Spoj iz bilo kojeg od patentnih zahtjeva 1-3 gdje najmanje jedno od E'* i E'" je -N(H)(alkoksikarbonil).
and R3 are each independently selected from the group consisting of halogen, -C1-5alkyl and C3-6cycloalkyl, wherein -C1-5alkyl and C3-6cycloalkyl may be each independently non-substituted, or substituted with halogen, -CN, -OC1-5alkyl or -C1-5alkyl, or R2 and R3, taken together with the carbon atom to which they are attached, may form C3-6cycloalkyl (wherein C3-6cycloalkyl may be non-substituted, or substituted with halogen, -OC1-5alkyl or -C1-5alkyl); 
i R3 su svaki neovisno odabrani iz skupine koja se sastoji od halogena, C1-5 alkil i C3-6 cikloalkil, gdje je C1-5 alkil i C3-6cikloalkil mogu biti svaki neovisno nesupstituirani ili supstituirani s halogenom, -CN, -OC1-5 alkil ili -C1-5 alkil, ili R2 i R3, zajedno s atomom ugljika na koji su vezani, mogu tvoriti C3-6 cikloalkil (gdje C3-6cikloalkil mogu biti ne supstituirani ili supstituirani halogenom, -OC1-5 alkil ili -C1-5 alkil);
“Alkynyl” means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. 
"alkinil" znači alifatska ugljikovodična skupina koja sadrži najmanje jednu trostruku vezu ugljik-ugljik i može biti nerazgranata ili razgranata i sadrži 2 do 15 atoma ugljika u lancu;
Of this embodiment, another embodiment is a method which further comprises the preparation of the compound of formula (4), or a pharmaceutically acceptable salt thereof, wherein a compound of formula (2): 
Postupak u skladu s patentnim zahtjevom 4, koji se dodatno sastoji u dobivanju spoja formule (4), naznačen time što se postupak sastoji u: oO a) reakciji spoja formule (2): ili njegove farmaceutski prihvatljive soli, s Grignardovim reagensom formule (3):
step b) conversion of carboxy group of a compound of formula (III) to carbamate to form a compound of formula (IV) 
Korak a) Pretvorba karboksi skupine spoja formule (III) [image] u karbamat, kako bi se tvorio spoj formule (IV) [image] u kojoj R je kao što je gore definirano;
The residue was dissolved in water and 0.1M HCl was added to pH=4. 
Ostatak je otopljen u vodi i dodana je 0.1 M HCI do pH = 4.
• Ar1 is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, each unsubstituted or substituted at a carbon ring member with one or two Ra moieties; 
• Ar1 je 2-piridil, 3-piridil, 4-piridil, 2-pirimidinil, 4-pirimidinil, 5-pirimidinil, ili fenil, svaki nesupstituiran ili supstituiran na ugljiku članu prstena sa jednom ili dvije Ra funkcionalne skupine;
The process of claim 13, wherein the color of the solution of hydrobromic acid in acetic acid is less than 1000 APHA. 
Postupak prema patentnom zahtjevu 13, naznačen time, da otopina bromovodične kiseline u octenoj kiselini jest 33% bromovodična kiselina u octenoj kiselini.
In another embodiment, in conjunction with any of the above or below embodiments, R1 is phenyl substituted by R2, and the phenyl is additionally substituted by 0, 1, 2 or 3 substituents independently selected from halo, nitro, cyano, C1-4alkyl, OC1-4alkyl, OC1-4haloalkyl, NHC1-4alkyl, N(C1-4alkyl)C1-4alkyl and C1-4haloalkyl. 
Spoj prema patentnom zahtjevu 1, naznačen time što R' je fenil supstituiran sa O ili 1 R* supstituenta, i fenil je dodatno supstituiran sa 0, 1, 2 ili 3 supstituenta nezavisno izabrana od halo, nitro, cijano, Craalkil, OC1.alkil, OC,.ahaloalkil, NHC..aalkil, N(Craalkil)Ci.aalkil i C,ahaloalkil.
The CD and DVD industries have for decades invested substantial sums of money in developing metal packaging. 
Industrije CD-a i DVD-a već desecima godina investiraju znatne sume novca u razvoj metalnog pakiranja.
In the above processes according to the invention the compression, in particular to tablets, can be effected using rotary press machines from different manufacturers. 
U skladu sa ovim izumom, u gore spomenutom postupku se kompresija, posebice u tablete, može izvesti korištenjem rotacijskih presa različitih dobavljača.
Typically the additional active compound (c) is selected from the group consisting of (a) PDE IV inhibitors and (b) cortiocosteroids. 
Kombinacija u skladu s patentnim zahtjevom 8, naznačena time, da je djelatni spoj (c) odabran iz skupine koju čine (a) B2-agonisti i (b) kortikosteroidi.
The composition for use according to any one of the preceding claims, wherein the disease is CMT. 
Smjesa za uporabu prema zahtjevu 1 ili 2, gdje je bolest CMT, poželjno CMTIA.
The dosage form according to claim 3, which contains an amount of pantoprazole magnesium dihydrate which corresponds to 80 mg of pantoprazole. 
Dozimni oblik prema zahtjevu 5, naznačen time, da sadrži jednu količinu pantoprazol magnezij dihidrata, koja odgovara za 80 mg pantoprazola (slobodna kiselina).
The composition of claim 13, wherein the at least two distinct lipid formulations differ in at least one cationic lipid, optionally wherein the at least two distinct lipid formulations further differ in the percentage of PEGylated lipid. 
Pripravak prema patentnom zahtjevu 13, naznačen time da se najmanje dvije jasno različite lipidne formulacije nadalje razlikuju u postotku lipida modificiranog s PEG.
A process for producing coloured glass in accordance with claim 12, comprising the following steps: Providing a molten glass matrix; 
Proces proizvodnje obojenog stakla, koji sadrži slijedeće korake; (i) < Osiguravanje matrice od rastopljenog stakla.
The method of claim 7, wherein said protein is P . aeruginosa exoprotein. 
Postupak uz skladu s patentnim zahtjevom 7, naznačen time što je navedeni protein egzoprotein iz bakterije P. aeruginosa.
The method according to claim 1, wherein the pouches are moved continuously through the manufacturing process. 
Postupak prema zahtjevu 1, naznačen time da se vrećice kroz postupak proizvodnje pomiču u šaržama.
Production of the Dosage Forms According to the Invention 
Priprema dozirnih oblika prema izumu
The method according to claim 18, wherein a fraction introduced in step (b) has a particle size in a range of from 10-30 mm. The method according to claim 18, wherein a fraction introduced in step (b) has a particle size in a range of from 30-70 mm. 
Postupak prema bilo kojem od zahtjeva 13 ili 14, naznačen time da su veličine čestica unutar frakcije u rasponu od 10 - 30 mm, poželjno u rasponu od 30 - 70 mm, još poželjnije u rasponu od 60-120 mm.
The pyridone derivative, or a salt thereof, according to any of claims 1 to 7, wherein R4 in the formula (I) represents a halogen atom, a cyano group, a C1-C6 haloalkyl group, a C1-C6 alkoxy group, a hydoxymethyl group, a C1-C6 alkyl group, or a C2-C6 alkenyl group. 
Derivat piridona ili njegova sol prema patentnim zahtjevima 1 do 7, naznačen time da je R4 u formuli (I) atom halogena, cijano grupa, C1-C6 haloalkil grupa, C1-C6 alkoksi grupa, hidrometil grupa, C1-C6 alkil grupa ili C2-C6 alkenil grupa.
A Compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R1 
Spoj formule I: ili njegov pojedinačni stereoizomer ili smjesa stereoizomera i izborno kao njegova farmaceutski prihvatljiva sol ili solvat, gdje
A compound selected from the group consisting of and or a pharmaceutically acceptable salt thereof. 
Spoj izabran iz grupe koja obuhvaća HR P20151111T1 ili njegova farmaceutski prikladna sol.
The method of any of the preceding claims, wherein diabetes mellitus type 2 is not adequately controlled with metformin and insulin alone. 
Kombinacija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što sami metformin i inzulin nisu dovoljna kontrola za dijabetes melitus tip 2.
A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound according to claims 1 or 2 and a pharmaceutically acceptable vehicle. 
Metoda za pripravu sastava, naznačena time da sadrži korak miješanja spoja ili farmaceutski prihvatljive soli spoja prema zahtjevu 1 ili 2 1 farmaceutski prihvatljivog nosača.
The syringe of any preceding claim, wherein the at least one first lug (34) further comprises at least one first surface (40), wherein the at least one first surface (40) extends from a first end of the base surface (38) to a most proximal end of the at least one third surface. 
Štrcaljka prema zahtjevu 4, naznačena time da barem jedna ušica (34) dodatno sadrži barem jednu površinu koja povezuje prvu površinu (40) i drugu površinu (42) na baznu površinu (38).
The pharmaceutical composition according to claim 6, wherein the compound is characterized in that it has a stabilizing effect on the structure of the mutant CFTR protein and/or blocks interaction with cellular proteins responsible for premature degradation of mutant CFTR protein. 
Modulator formule (I) u skladu s patentnim zahtjevom 1, za uporabu u liječenju cistične fibroze pri čemu on ima stabilizirajući učinak na strukturu mutiranog CFTR proteina i/ili blokira međudjelovanje sa staničnim proteinima odgovornim za preuranjenu razgradnju mutiranog CFTR.
The pharmaceutical composition or dosage form of any one of claims any one of claims 1 to 15 for use in a method of treating or preventing a disorder or condition associated with a digestive enzyme deficiency. 
Kompozicija ili dozna forma u skladu sa zahtjevima 1 do 13, za primjenu u postupcima tretiranja ili prevencije poremećaja ili stanja povezanih sa nedostatkom digestivnih enzima kod pacijenata.
The system of claim 11, wherein actuation of said tool is controlled by one or more user interface on said input device. 
pri čemu se savijanje navedenog drugog zgloba kontrolira pomoću napetosti na navedenom jednom ili više izduženih elemenata.
The composition of claim 22, wherein the composition is in the form of a tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment, lotion, or paste. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time što je navedeni pripravak u obliku kreme, gela, suspenzije, masti, paste, disperzije ili emulzije.
In another preferred embodiment of the pharmaceutical methods and means of the invention, the CD19xCD3 bispecific single chain antibody construct is to be administered in a daily dose of 10µg to 100µg per square meter patient body surface area. 
Konstrukt za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time što se CD19xCD3 konstrukt protutijela bispecifičnog jednostrukog lanca daje u dnevnoj dozi od 15 ug do 30 ug po kvadratnom metru površine tijela pacijenta.
the proportion of the herbicidal sulfonylurea compound or its salt is from 0.5 to 50 parts by weight, the proportion of the inorganic salt is 1 to 20 parts by weight, the proportion of the sulfonate is 0.1 to 20 parts by weight. 
omjer herbicidnog spoja sulfoniluree ili njegove soli iznosi od 0,5 do 50 masenog udjela, udio anorganske soli je od 1 do 20 masenog udjela, udio sulfonata je od 0,1 do 20 masenog udjela.
an X-Ray powder diffraction (XRPD) pattern substantially the same as shown in Figure 2; 
(a) spektar difrakcije X-zraka praha (XRPD), isti kao što je prikazan na Slici 2;
Packaging unit according to claim 6, wherein the label comprises an average surface roughness between 0.1 and 100 µm, preferably between 0.5 and 10 µm, and most preferably between 1 and 4 µm. 
Jedinica za pakiranje prema zahtjevu 6, naznačena time da naljepnica ima prosječnu hrapavost površine između 0.1 i 100 um, poželjno između 0.5 i 10 um, te najpoželjnije između 1 14 um.
wt% of microcrystalline cellulose by weight of the composition; 
mas% mikrokristalne celuloze, u odnosu na masu pripravka;
The phthalimido starting materials can again be obtained conventionally, e.g. 
Fialimido polazni materijali mogu se opel dobili konvencionalno, npr.
Preferably, the antibody prepared in step (b) in the above methods is a monoclonal antibody. 
Postupak prema zahtjevu 17, gdje to protutijelo ili fragmenti protutijela izabranog u koraku (c) inhibira vezanje
The composition for use according to claim 9, or the use according to claim 10, or the compound for use according to claim 11, wherein the anti-inflammatory agent is selected from the group consisting of: an analgesic; an antirheumatic agent; a gastrointestinal agent; a gout preparation; glucocorticoids; ophthalmic preparation; respiratory agent; a nasal preparation; and a mucous membrane agent. 
Pripravak za uporabu prema zahtjevu 9, ili uporaba prema zahtjevu 10, ili spoj za uporabu prema zahtjevu 11. naznačen time da je protuupalno sredstvo odabrano iz skupine koju čine: analgetik; antireumatsko sredstvo; gastrointestinalno sredstvo; pripravak protiv gihta; glukokortikoidi; oftalmički pripravak; respiratorno sredstvo; nazalni pripravak; te sredstvo za sluznicu.
Alternatively, the second hydrophobic material comprises from 5% to 25%, from 10% to 20%, from about 10% to 25%, from 15% to 25%, from 22% to 28%, or from 5% to 15% of the weight of the particles. In certain embodiments, the invention is directed to a pharmaceutical oral dosage form comprising a) a plurality of particles comprising an opioid antagonist dispersed in a melt-extruded matrix comprising a first hydrophobic material and a layer comprising a second hydrophobic material disposed about each of the particles, the second hydrophobic material comprising, from 2% to 30% of the weight of the particles; b) a plurality of particles comprising an opioid agonist dispersed in a third hydrophobic material; and c) a capsule containing the plurality of opioid agonist particles and the plurality of opioid antagonist particles. 
Farmaceutski proizvod koji sadrži: a) mnoštvo ekstrudiranih čestica, od kojih svaka čestica sadrži opioidni antagonist disperziran u matriksu; b) sloj koji pokriva najmanje dio ekstrudiranih čestica; matriks i sloj koji odvajaju opioidni antagonist u čistom dozirajućem obliku, i drugo mnoštvo farmaceutski prihvatljivih čestica, od kojih svaka od drugog mnoštva čestica sadrži opioidni agonist disperziran u matriksu, naznačen time da matriks prvog mnoštva čestica sadrži prvi hidrofobni materijal, gdje sloj sadrži drugi hidrofobni materijal u količini od oko 5% do oko 30%, od oko 16% do oko 30%, od oko 20% do oko 29%, ili od oko 22% do oko 28% težine ekstrudiranih čestica i matriks drugog mnoštva čestica sadrži treći hidrofobni materijal, a opioidne čestice agonista su poželjno formirane ekstruzijom.
The reel according to any one of claims 12 to 15, characterized in that, a light-transmitting body is disposed in the hole of the second information display portion to transmit light. The reel according to any one of claims 1 to 4, characterized in that, the first information display portion is a wall member erected from the surface of the flange, and includes a recess and a protrusion at an upper edge. 
Kalem prema bilo kojem od zahtjeva 1 do 4, naznačen time, da najmanje jedan od prvog odsječka za prikaz informacije i drugog odsječka za prikaz informacije predstavlja zidni element koji je uzdignut od površine prirubnice, i obuhvaća udubinu (9b, 12b, 31b, 33b, 41b, 43b, 51b, 53b, 61b, 63b) i izbočinu (9a, 12a, 31a, 33a, 41a, 43a, 51a, 53a, 61a, 63a) na gornjem bridu.
Example 8: Evaluation of the beverages 
Datum podnošenja europske prijave patenta:
The polypeptide of claim 10, wherein said polypeptide comprises SEQ ID NO: 177. 
Polipeptid u skladu s patentnim zahtjevom 1, pri čemu je navedeni polipeptid SEQ ID NO: 177.
an enteric coating which provides for release of the bisphosphonate and the EDTA in the lower gastrointestinal tract of a mammal; 
Cc) enteričkog sloja koji služi za oslobađanje bisfosfonata i EDTA u nižem gastrointestinalnom traktu sisavaca; naznačen time da je molarni omjer dinatrijeve EDTA u bisfosfonatu najmanje 2:1.
deprotecting the protected glatiramer acetate with a solution of hydrobromic acid in acetic acid, which solution has been pretreated with a bromine scavenger in order to remove free bromine, to form trifluoroacetyl glatiramer acetate; 
uklanjanje zaštite sa zaštićenog glatiramer acetata otopinom bromovodične kiseline u octenoj kiselini, koja otopina sadrži manje od 0,5% slobodnog broma i manje od 1000 ppm nečistoća metalnim ionima, da se formira trifluoroacetil glatiramer acetat.
Trans Fatty Acids g/100g A method of obtaining a sturgeon-derived oil wherein the oil is extracted from membrane of sturgeon roe sacks following separation of the roe from the roe sacks. 
Postupak dobivanja ulja koje potječe od jesetre, naznačeno time, da se ulje ekstrahira iz membrane jajnika jesetre poslije odvajanja ikre od jajnika.
A system according to any of paragraphs a) to m) wherein the base plate unit 20 is made of massive and/or expanded thermoplastic and/or thermoset and/or metal material, preferably of plastics material (thermoplasts or thermosets). 
Sustav temeljem bilo kojeg od zahtjeva 1 do 6 pri čemu je jedinica bazne ploče (20) izrađena od masivnog ili ekspandiranog termoplastičnog i/ili termoformiranog i/ili metalnog materijala.
After stirring for 1.5 hrs at room temperature the reaction was complete. 
Nakon miješanja od 1,5 h na sobnoj temperaturi reakcija je dovršena.
subsequently reacting the latter in an inert solvent in the presence of a suitable base with the compound of the formula (VIIIa) 
(VID), zatim reakcijom potonjeg u inertnom otapalu u prisutnosti pogodne baze sa spojem s formulom (VIIIa) NC
The attenuated virus of item 1, wherein the modified protein encoding sequence and the parent protein encoding sequence encode the same protein. The attenuated virus of item 1, wherein the modified protein encoding sequence encodes a protein that differs from a natural isolate by about 10 amino acids or fewer. 
Oslabljeni virus prema zahtjevu 1., naznačen time što a) se sekvenca koja kodira modificirani protem kodira protein koji razlikuje od prirodnog izolata za 10 aminokiselina ili manje, ili b) se sekvenca koja kodira modificirani protein kodira protein koji razlikuje od prirodnog izolata za 20 aminokiselina ili manje.
The camphorsulphonic acid salt of (10 g) was dissolved in a mixture of hot absolute ethanol (170 ml) and ethanol (30 ml). 
Sol kamforsulfonske kiseline (10 g) se otopi u smjesi vrućeg apsolutnog etanola (170 ml) i metanola (30 ml).
treating said compound of formula IIIb.1 with a compound of formula IIb.1, where PG is a protecting group, to form a compound of formula Ib.1; and 
- obrade navedenog spoja formule IIIb.1 spojem formule IIb.1, gdje je PG zaštitna skupina, kako bi se dobio spoj formule Ib.1; 1
The aqueous phase was washed with ethyl acetate (290mL) and the mixture allowed to settle and the aqueous phase was separated and acidified to pH 1-2 by the addition of concentrated hydrochloric acid (18mL). 
Vodenu fazu ispere se etil-acetatom (290 ml), smjesu ostavi da se slegne, a vodenu fazu odvoji, te dodavanjem koncentrirane klorovodične kiseline (18 ml)zakiseli do pH 1-2.
The herbicidal mixtures according to the invention exert a greater herbicidal action than would have been expected according to Colby on the basis of the observed effects of the individual components when used alone. 
Herbicidne smjese prema izumu pokazuju veće herbicidno djelovanje nego što bi se to očekivalo prema Colby-u na temelju zabilježenih efekata pojedinačnih komponenti kada se koriste posebno.
An electrically heated smoking system according to any preceding claim, wherein the at least one heater comprises an end heater for heating the end of the aerosol-forming substrate, the end heater comprising one or more electrically conductive tracks on an electrically insulating substrate. 
Električno grijani sustav za pušenje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što jedna ili više električno vodljivih tračnica (203) se nalazi s unutrašnje strane cijevi od električno izolirajuće podloge (201).
A system according to any preceding clause, in which the male connection member (300, 1200) is a giving set spike for the administration of medical fluids, and the female connection member (10, 1010) forms an access port into a medical fluid container. 
Sustav prema bilo kojem prethodnom zahtjevu, naznačen time da je muški spojni element (300, 1200) namijenjen kao šiljak za probadanje za davanje medicinskih fluida, a ženski spojni element (10, 1010) tvori pristupni priključak u spremnik medicinskog fluida.
After 2 h stirring at room temperature, the reaction mixture was neutralized with a saturated aqueous solution of sodium hydrogencarbonate and the product was extracted into ethyl acetate. 
Nakon 2 sata miješanja na sobnoj temperaturi reakcijsku smjesu se neutralizira zasićenom vodenom otopinom natrijevog hidrogenkarbonata, a produkt ekstrahira u etil-acetat.
Pharmaceutical composition for use according to one of the claims 1 to 11, wherein the unit dosage form comprises the antibody or antigen-binding fragment thereof as liquid formulation in a hermetically sealed container selected from the group consisting of a vial, a sachette, a pre-filled syringe, a pre-filled autoinjector, a cartridge for a reusable syringe, and an applicator. 
Farmaceutski pripravak za uporabu u skladu s jednim od patentnih zahtjeva 1 do 11, naznačen time da oblik jediničnog doziranja sadrži protutijelo ili njegov fragment koji veže antigen kao tekuću formulaciju i u hermetički zatvorenoj posudi odabranoj iz skupine koju čine bočica, vrećica, prethodno napunjena štrcaljka, prethodno napunjeni autoinjektor, uložak za višekratnu štrcaljku, i aplikator.
An antibody directed against the extracellular part of Sortilin and capable of inhibiting binding of a pro-neurotrophin to a binding site on the Sortilin receptor, wherein the antibody is directed against a sequence consisting of RGGRIFRSSDFAKNF for use in treatment of human neurodegenerative disorders. 
Protutijelo usmjereno prema izvanstaničnom dijelu Sortilina koje je sposobno inhibirati vezanje pro-neurotrofina za vezno mjesto receptora Sortilina, pri čemu se protutijelo veže za motiv vezanja za pro-neurotrofin u skladu sa SEQ ID NO:25, 26, 27 ili 28 ili za njegov fragment.
means for preserving and administering washing solutions, and 
- sredstva za čuvanje i administraciju otopine za pranje, kao što su vreće ili slično,
The number of occurrences is listed. 
Broj objave europskog patenta:
The recording media of claim 1, comprising commands to cause the computer to perform in case that several target frequency bands are determined, that in step (c) the corresponding acoustic signals are outputted in order of damage severity, or outputted randomly. 
Medij za snimanje u skladu s patentnim zahtjevom 1, naznačen time što sadrži naredbe koje u slučaju da se odredi više ciljanih frekvencijskih pojaseva uzrokuju da računalo u koraku (c) daje na izlaz odgovarajuće zvučne signale prema veličini težine oštećenja, ili ih daje na izlaz nasumično.
cyclizing Compound 22 to produce Compound 21, wherein X is selected from the group consisting of S, O and NH. 
(d) ciklizaciji Spoja 22 kako bi se dobilo Spoj 21, gdje X se bira iz skupine koju čine S, OiNH.
The antibody may be a monoclonal antibody. In further embodiments, the antibody is a chimeric or humanized antibody or a fragment of a natural antibody. 
Primjena zahtjeva 6, pri čemu je antitijelo monoklonsko, kimerično ili humaniziranog antitijela ili fragmenta antitijela koji se vezuje za antigen.